Abingdon will utilize the resources of Stason Pharma Japan to enhance its business development and intellectual property licensing opportunities in Asia.
Abingdon will also offer strategic planning, clinical development and regulatory science support for companies in Japan and throughout Asia wishing to register pharmaceuticals, biotech products and medical devices in the US via Stason Pharma Japan.
Richard Lebovitz, CEO of Abingdon, said: “This expansion will compliment Abingdon’s continued growth within the US and is a major step forward in the current economic climate. Our relationship with Stason has been beneficial for both companies and we believe this expansion will further strengthen the alliance.”